OF
AVBP icon

Optimize Financial’s ArriVent BioPharma AVBP Stock Holding History

Optimize Financial’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$436K Buy
+18,916
New +$427K 0.21% 161

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Optimize Financial's AVBP Position: Q1 2026 in Review

Optimize Financial opened a new position in ArriVent BioPharma (AVBP) in Q1 2026: 18,916 shares worth $436K. The stake represents 0.21% of the portfolio and ranks #161 among its holdings.

139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Optimize Financial held 18,916 shares of ArriVent BioPharma worth $436K as of Q1 2026.
  • ArriVent BioPharma was a new Optimize Financial position in Q1 2026.
  • ArriVent BioPharma made up 0.21% of Optimize Financial's portfolio in Q1 2026, its #161 holding.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Optimize Financial's 13F filing for Q1 2026, filed 12 May 2026.